Raymond James Financial Services Advisors, Inc. Krystal Biotech, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 1,348 shares of KRYS stock, worth $246,710. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,348
Previous 1,313
2.67%
Holding current value
$246,710
Previous $241,000
1.66%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding KRYS
# of Institutions
313Shares Held
24.7MCall Options Held
417KPut Options Held
485K-
Black Rock Inc. New York, NY3.95MShares$723 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.82MShares$517 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.66MShares$487 Million6.67% of portfolio
-
State Street Corp Boston, MA1.36MShares$248 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA942KShares$172 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.7B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...